Loading...
Market
How will Novo Nordisk's stock price change by the end of 2024 following the FLOW trial results?
4
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Stock market data
Story
Novo Nordisk's Ozempic Shows Benefits in FLOW Trial for Diabetes and Kidney Disease
May 24, 2024, 10:34 AM
Novo Nordisk's Ozempic (semaglutide) has shown significant benefits in a clinical trial for patients with type 2 diabetes and chronic kidney disease. The FLOW trial demonstrated that weekly doses of semaglutide reduced the risk of major kidney events, cardiovascular events, and death from any cause. Additionally, the medication slowed the progression of kidney function decline. New data revealed that semaglutide cut the risk of clinically important kidney outcomes and death from cardiovascular causes. The findings were presented at the ERA24 conference.
View original story
Similar markets
Stock price increases by more than 20% • 25%
Stock price increases by 10-20% • 25%
Stock price increases by less than 10% • 25%
Stock price decreases • 25%
Increase over 200% • 25%
Increase 100-200% • 25%
Increase up to 100% • 25%
Decrease or no change • 25%
<20% • 25%
20%-40% • 25%
40%-60% • 25%
>60% • 25%
Profit decline over 20% • 25%
Profit decline 10-20% • 25%
Profit decline less than 10% • 25%
No significant change or profit increase • 25%
Decrease by more than 10% • 33%
No significant change • 33%
Increase by more than 10% • 33%
10-20% increase • 25%
21-50% increase • 25%
51-100% increase • 25%
more than 100% increase • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Significant Increase (>15%) • 33%
Moderate Increase (5-15%) • 33%
Little to No Change (<5%) • 33%
Increase by over 50% • 25%
Increase by less than 50% • 25%
Decrease • 25%
Remain stable (±10%) • 25%
20% increase or more • 25%
10-20% increase • 25%
0-10% increase • 25%
No increase or decrease • 25%
